These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9854223)

  • 41. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
    Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
    N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevated hCG as an isolated finding during the second trimester biochemical screen: genetic, ultrasonic, and perinatal significance.
    Fejgin MD; Kedar I; Amiel A; Ben-Tovim T; Chen R; Petel Y; Tepper R
    Prenat Diagn; 1997 Nov; 17(11):1027-31. PubMed ID: 9399350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An economic evaluation of second-trimester genetic ultrasonography for prenatal detection of down syndrome.
    Vintzileos AM; Ananth CV; Fisher AJ; Smulian JC; Day-Salvatore D; Beazoglou T; Knuppel RA
    Am J Obstet Gynecol; 1998 Nov; 179(5):1214-9. PubMed ID: 9822503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Normal midtrimester (17-20 weeks) genetic sonogram decreases amniocentesis rate in a high-risk population.
    Pinette MG; Garrett J; Salvo A; Blackstone J; Pinette SG; Boutin N; Cartin A
    J Ultrasound Med; 2001 Jun; 20(6):639-44. PubMed ID: 11400938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contribution of ultrasonographic examination to the prenatal detection of trisomy 21: experience from 19 European registers.
    Wellesley D; De Vigan C; Baena N; Cariati E; Stoll C; Boyd PA; Clementi M;
    Ann Genet; 2004; 47(4):373-80. PubMed ID: 15581835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Results and views of women in population-wide pregnancy screening for trisomy 21 in east Finland.
    Heikkilä A; Ryynänen M; Kirkinen P; Saarikoski S
    Fetal Diagn Ther; 1997; 12(2):93-6. PubMed ID: 9218949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aberrant right subclavian artery in Down syndrome fetuses.
    Fehmi Yazıcıoğlu H; Sevket O; Akın H; Aygün M; Özyurt ON; Karahasanoğlu A
    Prenat Diagn; 2013 Mar; 33(3):209-13. PubMed ID: 23319208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The "genetic sonogram": comparison of the index scoring system with the age-adjusted US risk assessment.
    Winter TC; Uhrich SB; Souter VL; Nyberg DA
    Radiology; 2000 Jun; 215(3):775-82. PubMed ID: 10831699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Echographic signs of trisomy 21 in the second trimester of pregnancy: actual value after analysis of the literature].
    Vautier-Rit S; Subtil D; Vaast P; Dufour P; Valat AS; Bourgeot P; Puech F
    J Gynecol Obstet Biol Reprod (Paris); 2000 Sep; 29(5):445-53. PubMed ID: 11011273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of genetic sonography to reduce the need for amniocentesis in women at high-risk for Down syndrome.
    Yeo L; Vintzileos AM
    Semin Perinatol; 2003 Apr; 27(2):152-9. PubMed ID: 12769201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Placental chorangiosis associated with markedly elevated maternal chorionic gonadotropin. A case report.
    Stroustrup Smith A; Huang WY; Wong G; Levine D
    J Reprod Med; 2003 Oct; 48(10):827-30. PubMed ID: 14619654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Trisomy 21. 209 cases from the French College of Fetal Ultrasonography. Pertinence of ultrasonographic signs].
    Le Duff D
    Contracept Fertil Sex; 1997 Dec; 25(12):VII-XIV. PubMed ID: 9497609
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical impact of systematic genetic sonogram screening in a low-risk population.
    Lauria MR; Branch MD; LaCroix VH; Harris RD; Baker ER
    J Reprod Med; 2007 May; 52(5):359-64. PubMed ID: 17583232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Re: Trisomy 21: 91% detection rate using second-trimester ultrasound markers.
    Hutchon DJ
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):83-4. PubMed ID: 11489234
    [No Abstract]   [Full Text] [Related]  

  • 55. Should sonographic screening for fetal Down syndrome be applied to low risk women?
    Benacerraf BR
    Ultrasound Obstet Gynecol; 2000 Jun; 15(6):451-5. PubMed ID: 11005109
    [No Abstract]   [Full Text] [Related]  

  • 56. Optimizing risk reduction in screening for Down syndrome.
    Wyatt PR
    Prenat Diagn; 2007 Dec; 27(13):1268. PubMed ID: 18046735
    [No Abstract]   [Full Text] [Related]  

  • 57. Rare major maternal complications after second trimester amniocentesis: sequelae of avoiding a transplacental approach.
    Kin LT; Ngong LT; Yeung LT; Wah SP; Hung TW
    Aust N Z J Obstet Gynaecol; 2001 Nov; 41(4):472-3. PubMed ID: 11787933
    [No Abstract]   [Full Text] [Related]  

  • 58. Prenatal screening for Down syndrome: tempering practice with policy.
    Haddow JE
    Ultrasound Obstet Gynecol; 2002 Jul; 20(1):103-4. PubMed ID: 12100435
    [No Abstract]   [Full Text] [Related]  

  • 59. Can the risk for Down syndrome be reliably modified by second-trimester ultrasonography?
    Palomaki GE; Haddow JE
    Am J Obstet Gynecol; 1995 Nov; 173(5):1639-40. PubMed ID: 7503224
    [No Abstract]   [Full Text] [Related]  

  • 60. DISQ 5: Counseling women with isolated 'soft' markers at 18-24 weeks.
    Alfirevic Z
    Ultrasound Obstet Gynecol; 2006 Sep; 28(3):355. PubMed ID: 16941486
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.